공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 약독생수두백신 시장(2020-2027년)

Global Varicella Attenuated Live Vaccine Market - 2020-2027

리서치사 DataM Intelligence
발행일 On Demand Report 상품 코드 987864
페이지 정보 영문 180 Pages
가격
US $ 3,750 ₩ 4,238,000 PDF & Excel (Single User License)
US $ 4,000 ₩ 4,521,000 PDF & Excel (Site License)
US $ 7,250 ₩ 8,194,000 PDF & Excel (Enterprise License)


세계의 약독생수두백신 시장(2020-2027년) Global Varicella Attenuated Live Vaccine Market - 2020-2027
발행일 : On Demand Report 페이지 정보 : 영문 180 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

칸디다증의 유병률 상승, 연구개발비의 증가 및 신흥 시장에서의 미개척 기회는 시장의 성장을 촉진하는 요인입니다. 그러나 개발도상 경제국에서 칸디다 질염에 관한 인식의 결여는 예측 기간 중 시장 성장을 방해할 것으로 전망됩니다.

세계의 약독생수두백신 시장에 대해 조사분석했으며, 시장의 개요, 시장 성장에 대한 영향요인, 각 부문·지역별 시장 규모와 전년대비 성장 및 주요 기업 등에 대해 분석하여 전해드립니다.

목차

제1장 세계의 약독생수두백신 시장 : 조사 범위·방법

  • 조사 방법
  • 조사 목적·범위

제2장 세계의 약독생수두백신 시장 : 시장의 정의·개요

제3장 세계의 약독생수두백신 시장 : 개요

  • 시장 내역 : 제품별
  • 시장 내역 : 애플리케이션별
  • 시장 내역 : 프로바이더별
  • 시장 내역 : 지역별

제4장 세계의 약독생수두백신 시장 : 시장 역학

  • 시장에 영향을 미치는 요인
    • 촉진요인
    • 억제요인
    • 시장 기회
    • 영향 분석

제5장 세계의 약독생수두백신 시장 : 업계 분석

  • Porter의 산업 분석
  • 공급망 분석
  • 밸류체인 분석
  • PEST 분석
  • 가격 분석
  • 규제 분석
  • 상환 분석
  • 미충족 요구
  • 특허 동향

제6장 세계의 약독생수두백신 시장 : COVID-19 분석

  • 시장에서 Covid-19의 분석
    • COVID-19 이전 시장 시나리오
    • 현재의 시장 시나리오
    • COVID-19 이후 또는 향후 시나리오
  • Covid-19 기간 중 가격 역학
  • 수요와 공급 스펙트럼
  • 팬데믹 기간 중 시장에 관련된 정부 구상
  • 제조업체의 전략적 구상

제7장 세계의 약독생수두백신 시장 : 제품별

  • 서론
  • 시장 규모 분석 및 전년대비 성장 분석(%) : 제품별
  • 시장 매력 지수 : 제품별
    • 1가 백신
    • 혼합백신

제8장 세계의 약독생수두백신 시장 : 애플리케이션별

  • 서론
  • 시장 규모 분석 및 전년대비 성장 분석(%) : 애플리케이션별
  • 시장 매력 지수 : 애플리케이션별
    • 수두 예방접종
    • 대상포진 예방접종
    • MMRV 예방접종

제9장 세계의 약독생수두백신 시장 : 프로바이더별

  • 서론
  • 시장 규모 분석 및 전년대비 성장 분석(%) : 프로바이더별
  • 시장 매력 지수 : 프로바이더별
    • 공공 프로바이더
    • 민간 프로바이더

제10장 세계의 약독생수두백신 시장 : 지역별

  • 서론
    • 시장 규모 분석 및 전년대비 성장 분석(%) : 지역별
    • 시장 매력 지수 : 지역별
  • 북미
    • 서론
    • 주요 지역 고유 역학
    • 시장 규모 분석 및 전년대비 성장 분석(%) : 제품별
    • 시장 규모 분석 및 전년대비 성장 분석(%) : 애플리케이션별
    • 시장 규모 분석 및 전년대비 성장 분석(%) : 프로바이더별
    • 시장 규모 분석 및 전년대비 성장 분석(%) : 국가별
  • 유럽
  • 남미
  • 아시아태평양
  • 중동·아프리카

제11장 세계의 약독생수두백신 시장 : 경쟁 구도

  • 경쟁 시나리오
  • 시장 포지셔닝/점유율 분석
  • 합병과 인수 분석

제12장 기업 개요

  • Bio-Med Pvt. Limited
    • 기업 개요
    • 제품 포트폴리오·설명
    • 주요 하이라이트
    • 재무 개요
  • Emcure Pharmaceuticals Limited
  • GC Pharma(Green Cross Holdings)
  • GlaxoSmithKline PLC
  • Novo Medi Sciences Pvt. Ltd.
  • Merck & Co. Inc.
  • Sanofi SA
  • Mitsubishi Tanabe Pharma Corporation
  • Takeda Pharmaceutical Company Limited

제13장 세계의 약독생수두백신 시장 : 중요 인사이트

제14장 세계의 약독생수두백신 시장 : DataM

  • 부록
  • DataM Intelligence·서비스 소개
  • 문의
KSA 21.02.22

Market Overview

Varicella zoster, also known as Human alphaherpesvirus 3, causes herpes zoster and chicken pox in humans. The infection instigated by this virus can be avoided by the use of vaccinations that are particularly formulated to provide immunity against the virus. These vaccines vary from each other on the basis of their contents. For instance, monovalent varicella vaccine comprises only one strain of virus whereas the combination varicella vaccine includes more than one strain of virus and offers immunity against more than one virus.

The global varicella attenuated live vaccine market size was worth US$ XX billion in 2019 and further predicted to reach US$ XX billion by 2027, at a CAGR of XX% during the forecast period (2020-2027).

Market Dynamics

Certain factors that are leading the market growth include the increasing prevalence of candidiasis, the increasing R&D expenditure, and untapped opportunities in the emerging markets. However, the lack of awareness regarding the vulvovaginal candidiasis in underdeveloped economies will hamper the market growth during the forecast period.

Expected increase in the prevalence of chicken pox

According to CDC (Centers for Disease Control and Prevention), more than 3.5 million cases of chickenpox, along with 9,000 hospitalizations, and 100 mortalities are averted by chickenpox vaccination in the U.S. This, in turn, contributes to the growth of the varicella attenuated live vaccine market. There are several companies that are strengthening their position by driving national programs for support and coordination among national, local, regional, and international stakeholders, has accomplished in improving immunization coverage rates.

Increasing government focus on varicella attenuated live vaccine

The government support is increasing with the rising focus on driving immunization programs to lessen the disease burden impact that aids in the growth of the varicella attenuated live vaccine market. A few of manufacturers in collaboration with Gavi, WHO, the World Bank, and UNICEF are committed to boost immunization programs and speed up the introduction of new vaccines. This would contribute to the growth of the varicella attenuated live vaccine market.

COVID-19 Impact Analysis

A decrease in the market value of varicella attenuated live vaccine is expected in 2020, backed by the decline in the hospital visits, which in turn, also hampered the functioning of immunization programs. Therefore, the demand for varicella attenuated live vaccine decreased amid the COVID-19 pandemic, which in turn, declined the sales of the vaccine in 2020.

Segment Analysis

Based on the application, the varicella attenuated live vaccine market has been classified into Chickenpox Immunization, Herpes Zoster Immunization, MMRV Immunization, and econazole.

Chickenpox Immunization segment contributed significant share to the global varicella attenuated live vaccine market in 2019

Chicken pox immunization contributed the largest varicella attenuated live vaccine market share in 2019, owing to immunization employed with an initial aim of developing immunity against chicken pox. It is highly contagious and is typically spread by direct contact or via air by sneezing and coughing. The illness commonly causes an itchy rash and leads to the formation of more than 400 blisters all over the body. Additionally, it causes fussiness, headache, and coughing in the patients.

Based on the product, the varicella attenuated live vaccine market has been classified into monovalent varicella vaccine and combination varicella vaccine.

Monovalent Varicella Vaccine lead the market throughout the forecast period

Monovalent Varicella Vaccine segment led the overall market with a share in 2019. It is also expected to foresee rapid growth during the forecast period, as such vaccines demonstrate lesser chances of causing febrile seizures in children as compared to combination vaccines. In addition, easy availability and presence of wide product portfolio are the other factors that enhance the varicella attenuated vaccine market growth.

Geographical Analysis

Based on geography, the study analyzes the varicella attenuated live vaccine market in the global market, including North America, South America, Europe, Asia-Pacific, and the Middle East & Africa.

North America leads the global market throughout the forecast period

North America dominated the global varicella attenuated live vaccine market with the largest share in terms of value and volume globally, followed by Europe and the Asia Pacific. The US dominated the North American varicella attenuated live vaccine market in 2019. The presence of skilled healthcare professionals and the presence of key market players, such as Merck & Co., Inc., are other factors that are supporting the market growth.

Moreover, Asia Pacific is expected to project the fastest growth rate in the varicella attenuated live vaccine market during the forecast period. China dominates the market, whereas India is estimated to exhibit considerable growth in the Asia Pacific varicella attenuated live vaccine market during the forecast period. The gradual rise in vaccination for varicella and the rapidly evolving life science industry are certain factors augmenting the market growth in the region.

Competitive Landscape

The varicella attenuated live vaccine market is highly competitive, owing to the large presence of varicella attenuated live vaccine brands. The key varicella attenuated live vaccine players include Bio-Med Pvt. Limited, GlaxoSmithKline PLC, GC Pharma (Green Cross Holdings), Novo Medi Sciences Pvt. Ltd., Emcure Pharmaceuticals Limited, Sanofi SA, Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation, and Takeda Pharmaceutical Company Limited. The crucial players are adopting new product launches and expansion strategies for global growth in the varicella attenuated live vaccine market.

Merck & Co. Inc.

Overview: Merck & Co. Inc. is a research-based pharmaceutical company that offer healthcare solutions via its prescription medicines, biologic therapies, vaccines, animal health products. The company sell its products to hospitals, drug wholesalers and retailers, government agencies, and other institutions. It generates over 40.0% of its revenue from the US.

Product Portfolio: The company's portfolio comprises VARIVAX and ZOSTAVAX.

Why Purchase the Report?

  • Visualize the varicella attenuated live vaccine market segmentation composition by product, application, provider, and region, highlighting the critical commercial assets and players.
  • Identify commercial opportunities in the varicella attenuated live vaccine market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of varicella attenuated live vaccine market - level 3 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global varicella attenuated live vaccine market report would provide access to an approx. 51 market data tables, 50 figures, and 260 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Varicella Attenuated Live Vaccine Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Varicella Attenuated Live Vaccine Market - Market Definition and Overview

3. Global Varicella Attenuated Live Vaccine Market - Executive Summary

  • 3.1. Market Snippet by Product
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by Provider
  • 3.4. Market Snippet by Region

4. Global Varicella Attenuated Live Vaccine Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of chicken pox
      • 4.1.1.2. Government initiatives to increase immunization programs
    • 4.1.2. Restraints:
      • 4.1.2.1. High Cost of the Vaccine
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Varicella Attenuated Live Vaccine Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. Global Varicella Attenuated Live Vaccine Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Varicella Attenuated Live Vaccine Market - By Product

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Segment
  • 7.3. Market Attractiveness Index, By Product Segment
    • 7.3.1. Monovalent Varicella Vaccine*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Combination Varicella Vaccine

8. Global Varicella Attenuated Live Vaccine Market - By Application

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
  • 8.3. Market Attractiveness Index, By Application Segment
    • 8.3.1. Chickenpox Immunization*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Herpes Zoster Immunization
    • 8.3.3. MMRV Immunization

9. Global Varicella Attenuated Live Vaccine Market - By Provider

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Provider Segment
  • 9.3. Market Attractiveness Index, By Provider Segment
    • 9.3.1. Public Provider*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Private Provider

10. Global Varicella Attenuated Live Vaccine Market - By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Provider
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Provider
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Provider
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Provider
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Provider
    • 10.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11. Global Varicella Attenuated Live Vaccine Market - Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Global Varicella Attenuated Live Vaccine Market- Company Profiles

  • 12.1. Bio-Med Pvt. Limited*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Emcure Pharmaceuticals Limited
  • 12.3. GC Pharma (Green Cross Holdings)
  • 12.4. GlaxoSmithKline PLC
  • 12.5. Novo Medi Sciences Pvt. Ltd.
  • 12.6. Merck & Co. Inc.
  • 12.7. Sanofi SA
  • 12.8. Mitsubishi Tanabe Pharma Corporation
  • 12.9. Takeda Pharmaceutical Company Limited

LIST NOT EXHAUSTIVE

13. Global Varicella Attenuated Live Vaccine Market - Premium Insights

14. Global Varicella Attenuated Live Vaccine Market - DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us
Back to Top
전화 문의
F A Q